Algert Global LLC Sells 77,626 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Algert Global LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 61.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 49,714 shares of the medical equipment provider’s stock after selling 77,626 shares during the quarter. Algert Global LLC’s holdings in Lantheus were worth $5,456,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Cerity Partners LLC grew its position in shares of Lantheus by 19.8% in the 3rd quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider’s stock valued at $1,306,000 after acquiring an additional 1,966 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the third quarter valued at approximately $25,955,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Lantheus during the 3rd quarter worth approximately $8,372,000. Landscape Capital Management L.L.C. acquired a new stake in Lantheus during the 3rd quarter valued at $435,000. Finally, Intech Investment Management LLC boosted its position in Lantheus by 219.4% during the third quarter. Intech Investment Management LLC now owns 49,131 shares of the medical equipment provider’s stock worth $5,392,000 after purchasing an additional 33,747 shares during the period. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research reports. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities reduced their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Performance

NASDAQ:LNTH opened at $90.52 on Monday. The company has a market cap of $6.29 billion, a price-to-earnings ratio of 15.06 and a beta of 0.51. The stock has a fifty day moving average price of $103.13 and a 200-day moving average price of $96.93. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.